Drug intelligence / Profile preview

SAS0421a

Development stage: Unknown
Lead developer: Apnimed
Modality: Small Molecules

Overview

SAS0421a is an experimental small molecule drug that is part of a combination pharmacological intervention (often studied alongside SAS0421b and SAS0421c) for the treatment of obstructive sleep apnea. The approach aims to target multiple pathophysiological mechanisms underlying obstructive sleep apnea, including stimulation of pharyngeal muscles, stabilization of ventilatory control, and increasing the arousal threshold. The drug has been evaluated in early-phase clinical trials as part of this multi-drug regimen. It was developed by Apnimed and Brigham & Women's Hospital.

Other names: SAS-0421aSAS0421aSAS 0421a

Beyond the preview

Go deeper on SAS0421a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAS0421a.

Explore the full profile